Morra E, Lazzarino M, Alessandrino E P, Inverardi D, Canevari A, Bernasconi C
Eur J Cancer Clin Oncol. 1984 Dec;20(12):1471-5. doi: 10.1016/0277-5379(84)90138-x.
Fifteen adult patients with refractory or relapsing acute lymphoblastic leukemia (ALL) received a 5-day remission induction regimen consisting of VP 16-213 (60 mg/m2 every 12 hr) and cytosine-arabinoside (100 mg/m2 every 12 hr) up to a maximum of three courses. The overall response rate was 60% (9/15), four patients (27%) achieving CR and five (33%) attaining PR. Responders were maintained with monthly courses of the same combination until progressive disease developed. The median duration of response was 4.5 months (2-12+ months). The regimen was relatively well tolerated. The major toxicity was hematologic. Non-hematologic toxicities included mild nausea and vomiting (11/15) and total alopecia (15/15). The results obtained with this combination are encouraging, in view of the poor prognosis associated with refractory or relapsing ALL in adults.
15例难治性或复发性急性淋巴细胞白血病（ALL）成年患者接受了为期5天的缓解诱导方案，该方案由VP 16 - 213（每12小时60mg/m²）和阿糖胞苷（每12小时100mg/m²）组成，最多进行三个疗程。总缓解率为60%（9/15），4例患者（27%）达到完全缓解（CR），5例（33%）达到部分缓解（PR）。缓解者每月接受相同组合的疗程维持治疗，直至疾病进展。缓解的中位持续时间为4.5个月（2 - 12 +个月）。该方案耐受性相对良好。主要毒性为血液学毒性。非血液学毒性包括轻度恶心和呕吐（11/15）以及全部脱发（15/15）。鉴于成人难治性或复发性ALL预后较差，该联合方案取得的结果令人鼓舞。
